Endonovo is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The company's primary product offering is SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. The company operates as a microcap biotech with extremely limited resources and liquidity.
Cyborg Score Rationale
The company has a market capitalization of $110K with trailing twelve-month revenue of $16K. The company has 1 employee and shows minimal commercial traction despite having novel technology platforms.
Top Insights
Operates with minimal staffing (1 employee as of February 2026) and extremely limited capital resources
Focuses on novel bioelectronic regenerative medicine approach with two distinct platforms (Immunotronics and Cytotronics)
Trading at penny stock levels ($0.0001 as of June 2026) with minimal liquidity and analyst coverage
Commercial-stage company but with negligible revenue generation and market validation to date
Named Competitors
BioElectronics — Bioelectronic medical devices
Tissue Engineering Platform — Advanced regenerative medicine solutions
Electroceutical Devices — Bioelectronic medicine for chronic conditions
Open the full interactive Endonovo Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.